InvestorsHub Logo
Followers 33
Posts 2436
Boards Moderated 0
Alias Born 03/02/2019

Re: None

Monday, 02/08/2021 10:48:11 PM

Monday, February 08, 2021 10:48:11 PM

Post# of 427453
Email sent to the reporter at her station email account.

Topic. Fish oil.
Maybe you should do a follow up with dr Bhatt of Brigham and women’s in Massachusetts about the amazing benefit of Vascepa or icosapent ethyl, published in NEJM 2018. The REDUCIT trial. Backed up by the EVAPORATE trial and the JELLIS trial.
Vascepa contains no DHA or DPA. It’s 96% EPA. It works where others don’t......likely because of her lacking DHA or DPA in the formulation. Some physicians with recently failed billion dollar trials are salty in my opinion and may have an ulterior motive not aligned with patient interest. Their timing in all of this is impeccable. Sorry if you had to deal with one.
See also the Cardiolink trial on covid 19 and the Prepare-It trial ongoing in Argentina for “prescription fish oil” and covid19. The results of these trials may astound you. Gilead also has top line results for two of their investigatorial drugs combined with Vascepa inbound at any moment.

Thank you for taking down the branded Vascepa picture atop your article.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News